Lovaza Manufacturer to Enter Consumer Healthcare Market

November 17, 2011

Pronova BioPharma (Lysaker, Norway) says it will enter the consumer healthcare market during the second half of 2012.

Answering to rising consumer interest in omega-3 products, Pronova BioPharma (Lysaker, Norway) says it will enter the consumer healthcare market during the second half of 2012. The company currently markets Omacor/Lovaza, the only omega-3 pharmaceutical drug approved for use by FDA and the EU.

Over the next 12 months, Pronova plans to build its consumer healthcare division by initiating clinical trials, adjusting manufacturing its manufacturing process for consumer products, and developing distribution channels.

Related Content:

Omega-3